ERAS vs GSK · $4.13B cap vs P/E 13, $103.31B cap
Erasca Inc (ERAS) versus GlaxoSmithKline PLC ADR (GSK) — a side-by-side from cached financials, not a winner call.
Erasca Inc (ERAS) is a biotechnology company listed on US.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
ERAS does not have a complete income-statement cache yet.
GSK does not have a complete income-statement cache yet.
ERAS currently screens at market cap $4.13B. GSK currently screens at market cap $103.31B and trailing P/E 13.5.
Not investment advice. Open the ERAS and GSK stock pages for the full models.
Not investment advice.